The Trump administration is close to issuing a new rule that could effectively ban rebate payments from drug manufacturers to pharmaceutical benefit managers, or PBMs. The plan is misguided. A full ban would backfire and increase costs to consumers.
- Transparency Hasn’t Stopped Drug Companies From Corrupting Medical Research
- Why CVS Is Giving Plans A New Tool To Target High Launch Prices